MTHFR polymorphisms and neurotoxicity and overall survival after methotrexate-based therapy in primary CNS lymphoma.
Karschnia P, Kurz S, Brastianos P, Winter S, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn J, Batchelor T, Plotkin S, Dietrich J. MTHFR polymorphisms and neurotoxicity and overall survival after methotrexate-based therapy in primary CNS lymphoma. Journal Of Clinical Oncology 2023, 41: 2079-2079. DOI: 10.1200/jco.2023.41.16_suppl.2079.Peer-Reviewed Original ResearchPrimary CNS lymphomaMethylenetetrahydrofolate reductase polymorphismPrimary CNS lymphoma patientsHD-MTXMethylenetetrahydrofolate reductaseOverall survivalC genotypeCNS lymphomaPatients treated with HD-MTXEffect of HD-MTXHD-MTX-based therapyAssociated with reduced overall survivalAssociation of MTHFR polymorphismsSeverity of leukoencephalopathyKaplan-Meier survival analysisProgression-free survivalLog-rank testMethylenetetrahydrofolate reductase genotypeAssociated with increased frequencyIntracellular folate metabolismAssociated with toxicityCerebral white matterInduction chemotherapyDecreased functional statusMassachusetts General Hospital